These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31238422)

  • 1. Bevacizumab versus ziv-aflibercept in branch retinal vein occlusion.
    Braimah IZ; Singh SR; Uplanchiwar B; Mansour AM; Chhablani J
    Indian J Ophthalmol; 2019 Jul; 67(7):1109-1113. PubMed ID: 31238422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
    Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
    Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy.
    Singh SR; Sahoo NK; Goud NR; Chhablani J
    Indian J Ophthalmol; 2019 Jul; 67(7):1114-1118. PubMed ID: 31238423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal Ziv-Aflibercept : Safety Analysis in Eyes Receiving More Than Ten Intravitreal Injections.
    Singh SR; Chattannavar G; Ayachit A; Pimentel MC; Alfaro A; Tiwari S; Heranjal A; Subramanyam A; Braimah IZ; Dhami A; Sachdev P; Mansour A; Chhablani J
    Semin Ophthalmol; 2020 Jan; 35(1):2-6. PubMed ID: 31690175
    [No Abstract]   [Full Text] [Related]  

  • 5. Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab.
    Ebrahimiadib N; Lashay A; Riazi-Esfahani H; Jamali S; Khodabandeh A; Zarei M; Roohipoor R; Khojasteh H; Bazvand F; Ojani M; Shahabinejad M; Yaseri M; Modjtahedi BS; Davoudi S; Riazi-Esfahani M
    Ophthalmic Surg Lasers Imaging Retina; 2020 Mar; 51(3):145-151. PubMed ID: 32211904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of intravitreal ziv-aflibercept in patients with macular edema following retinal vein occlusion in Korle-Bu Teaching Hospital, Ghana: a retrospective case series.
    Braimah IZ; Agyabeng K; Amoaku WM
    Int Ophthalmol; 2021 Jul; 41(7):2445-2453. PubMed ID: 33782846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
    Pichi F; Elbarky AM; Elhamaky TR
    Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
    Braimah IZ; Agarwal K; Mansour A; Chhablani J;
    Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of Macular Thickness and Visual Acuity in DME Treated by Two Doses of Intravitreal Ziv-Aflibercept Versus Bevacizumab: Analysis of a Randomized, Three-Armed Clinical Trial.
    Jabbarpoor Bonyadi MH; Baghi A; Ramezani A; Yaseri M; Soheilian M
    Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):684-690. PubMed ID: 31755967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
    Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
    Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
    Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
    Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
    Kim M; Jeong S; Sagong M
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year outcomes of intravitreal ziv-aflibercept.
    Mansour AM; Ashraf M; Charbaji A; Younis MH; Souka AA; Dogra A; Mansour HA; Chhablani J;
    Br J Ophthalmol; 2018 Oct; 102(10):1387-1390. PubMed ID: 29317400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PERIPHERAL ISCHEMIC RETINAL PHOTOCOAGULATION IN ADDITION TO INTRAVITREAL BEVACIZUMAB VERSUS INTRAVITREAL BEVACIZUMAB ALONE FOR THE TREATMENT OF MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION: A Randomized Double-Masked Controlled Clinical Trial.
    Nourinia R; Emamverdi M; Ramezani A; Amizadeh Y; Khorshidifar M; Behnaz N; Safi S
    Retina; 2020 Jun; 40(6):1110-1117. PubMed ID: 31157710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion.
    Son BK; Kwak HW; Kim ES; Yu SY
    Korean J Ophthalmol; 2017 Jun; 31(3):209-216. PubMed ID: 28471106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-Year Results of a Trial Comparing 2 Doses of Intravitreal Ziv-aflibercept versus Bevacizumab for Treatment of Diabetic Macular Edema.
    Jabbarpoor Bonyadi MH; Baghi A; Ramezani A; Yaseri M; Soheilian M
    Ophthalmol Retina; 2018 May; 2(5):428-440. PubMed ID: 31047323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions.
    Tomomatsu Y; Tomomatsu T; Takamura Y; Gozawa M; Arimura S; Takihara Y; Inatani M
    Acta Ophthalmol; 2016 May; 94(3):e225-30. PubMed ID: 25989706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.
    Karasu B; Gunay BO
    Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):99-106. PubMed ID: 31768680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Early Anatomical and Functional Responses to Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion.
    Noh D; Ryu G; Lee J; Sagong M
    Ophthalmologica; 2018; 239(4):194-204. PubMed ID: 29393235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.